Adjuvant radiation therapy and survival for adenoid cystic carcinoma of the breast

Sun, Jiayuan; Wu, San‐Gang; Chen, Shanyu; Li, Fengyan; Lin, Huan‐Xin; Chen, Yongxiong; He, Zhen-Yu

doi:10.1016/j.breast.2016.11.017

Cited by 22 publications

(31 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mean 5-years OS reported in retrospective series was 89.7% [2,16,17]. Mean 10-years OS reported in retrospective series was 78.7% [5,16,17].…”

Section: Resultsmentioning

confidence: 87%

See 1 more Smart Citation

The role of radiotherapy (RT) in the treatment of Adenoid Cystic Carcinoma of the Breast: case report of RT retreatment and literature review

Smaniotto¹,

Terribile²,

Marazzi³

et al. 2019

View full text Add to dashboard Cite

This study reviews the recent literature on the role of definitive radiotherapy (RT) in the management of adenoid cystic carcinoma of the breast (ACCB) and presents comprehensive data on clinical outcomes. A case report of radiotherapy retreatment in ACCB is reported for first time in literature. Methods: The authors performed a literature review using PubMed (1981-2019) to identify all studies that match with keywords. Inclusion criteria were articles reporting patients underwent radiotherapy after ACCB diagnosis with follow up reporting. Data analyzed were number of pts, age, study design, multimodality treatment management with radiotherapy schedule, stage of disease, pathological risk factors, local relapse free survival (LFRS), metastases free survival (MFS) and overall survival (OS). Results: Of the 60 identified studies, 15 met the inclusion criteria. All studies had a retrospective design. Overall, 967 patients (median, 64; range, 1-478) were included. A high heterogeneity was found across studies in terms of pathological features available, local approach in multimodality management, adjuvant RT administration, and reported outcomes. Mean LRFS reported by case reports was 24 months (range 20-48). Mean DFS reported by case series and retrospective series was 87.9% (range 69-100%). Mean OS reported in case reports was 30 months (range 12-84). Mean 5-years OS reported in retrospective series was 89.7%. Mean 10-years OS reported in retrospective series was 78.7%. In some retrospective series radiotherapy was found significantly related to local control (p=0.03) and with an absolute survival benefit of 9% at 5 year and of 21% at 10 years (p=0.005). Conclusion and implications for practice: To our knowledge this is the first report on radiotherapy retreatment in ACCB local relapse. This study also reviews the recent literature on the role of adjuvant RT in the management of ACCB and presents comprehensive data on long-term clinical outcome. Some significant results about RT are improvement in local control and survival benefit also since at 10 years in some series. Further studies are needed to confirm these results.

show abstract

“…Mean 5-years OS reported in retrospective series was 89.7% [2,16,17]. Mean 10-years OS reported in retrospective series was 78.7% [5,16,17].…”

Section: Resultsmentioning

confidence: 87%

“…Mean OS reported in case reports was 30 months (range 12-84) [3,4,8,[10][11][12]. Mean 5-years OS reported in retrospective series was 89.7% [2,16,17]. Mean 10-years OS reported in retrospective series was 78.7% [5,16,17].…”

Section: Resultsmentioning

confidence: 99%

The role of radiotherapy (RT) in the treatment of Adenoid Cystic Carcinoma of the Breast: case report of RT retreatment and literature review

Smaniotto¹,

Terribile²,

Marazzi³

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The use of adjuvant RT is recommended in lacrimal gland ACC as well as following breastconserving surgery for breast ACC (188)(189)(190)(191). However, the role of adjuvant RT in the Fig.…”

Section: Discussionmentioning

confidence: 99%

Molecular features of adenoid cystic carcinoma with an emphasis on microRNA expression

Andreasen

2018

APMIS

View full text Add to dashboard Cite

“…Therefore, the mainstay of treatment in males closely aligns with that in females with the majority of surgeons opting to omit radiotherapy . Although radiotherapy may improve both cause‐specific and overall survival rates, given the patients age, tumor size, negative sentinel node biopsy, and confirmation of clear margins on surgical excision, the decision not to proceed with radiotherapy in this instance was reasonable.…”

Section: Summary Of All Reported Adenoid Cystic Carcinoma Of the Breamentioning

confidence: 99%

“…20 Therefore, the mainstay of treatment in males closely aligns with that in females with the majority of surgeons opting to omit radiotherapy. 1 Although radiotherapy may improve both cause-specific and overall survival rates, 21,22 given the patients age, tumor size, negative sentinel node biopsy, and confirmation of clear margins on surgical excision, the decision not to proceed with radiotherapy in this instance was reasonable. This case reaffirms the importance of routine histopathology in mastectomy for cosmetic gynecomastia in males and contributes to the limited but growing base of literature available for treatment and prognostication of ACCB in males.…”

mentioning

confidence: 98%

Gynecomastia or rare malignancy? A young man with an unremarkable history proves to have adenoid cystic carcinoma of the breast

Mackenzie

Douglas

2020

Breast J

View full text Add to dashboard Cite

Adjuvant radiation therapy and survival for adenoid cystic carcinoma of the breast

Cited by 22 publications

References 19 publications

The role of radiotherapy (RT) in the treatment of Adenoid Cystic Carcinoma of the Breast: case report of RT retreatment and literature review

The role of radiotherapy (RT) in the treatment of Adenoid Cystic Carcinoma of the Breast: case report of RT retreatment and literature review

Molecular features of adenoid cystic carcinoma with an emphasis on microRNA expression

Gynecomastia or rare malignancy? A young man with an unremarkable history proves to have adenoid cystic carcinoma of the breast

Contact Info

Product

Resources

About